GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innoviva Inc (NAS:INVA) » Definitions » Cyclically Adjusted PB Ratio

Innoviva (Innoviva) Cyclically Adjusted PB Ratio : 7.46 (As of Jun. 05, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Innoviva Cyclically Adjusted PB Ratio?

As of today (2024-06-05), Innoviva's current share price is $15.88. Innoviva's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $2.13. Innoviva's Cyclically Adjusted PB Ratio for today is 7.46.

The historical rank and industry rank for Innoviva's Cyclically Adjusted PB Ratio or its related term are showing as below:

INVA' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 6.87   Med: 20.24   Max: 150
Current: 7.49

During the past years, Innoviva's highest Cyclically Adjusted PB Ratio was 150.00. The lowest was 6.87. And the median was 20.24.

INVA's Cyclically Adjusted PB Ratio is ranked worse than
85.76% of 660 companies
in the Biotechnology industry
Industry Median: 1.745 vs INVA: 7.49

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Innoviva's adjusted book value per share data for the three months ended in Mar. 2024 was $11.206. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $2.13 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Innoviva Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Innoviva's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innoviva Cyclically Adjusted PB Ratio Chart

Innoviva Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 29.94 11.45 8.48

Innoviva Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.27 8.16 7.56 8.48 7.16

Competitive Comparison of Innoviva's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Innoviva's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innoviva's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innoviva's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Innoviva's Cyclically Adjusted PB Ratio falls into.



Innoviva Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Innoviva's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=15.88/2.13
=7.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Innoviva's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Innoviva's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=11.206/131.7762*131.7762
=11.206

Current CPI (Mar. 2024) = 131.7762.

Innoviva Quarterly Data

Book Value per Share CPI Adj_Book
201406 -1.655 100.560 -2.169
201409 -1.676 100.428 -2.199
201412 -1.921 99.070 -2.555
201503 -2.228 99.621 -2.947
201506 -2.512 100.684 -3.288
201509 -2.751 100.392 -3.611
201512 -2.985 99.792 -3.942
201603 -3.203 100.470 -4.201
201606 -3.257 101.688 -4.221
201609 -3.358 101.861 -4.344
201612 -3.255 101.863 -4.211
201703 -3.060 102.862 -3.920
201706 -2.713 103.349 -3.459
201709 -2.064 104.136 -2.612
201712 -2.383 104.011 -3.019
201803 -2.108 105.290 -2.638
201806 -1.550 106.317 -1.921
201809 -1.102 106.507 -1.363
201812 1.519 105.998 1.888
201903 1.860 107.251 2.285
201906 2.238 108.070 2.729
201909 2.637 108.329 3.208
201912 3.095 108.420 3.762
202003 3.746 108.902 4.533
202006 4.506 108.767 5.459
202009 4.789 109.815 5.747
202012 5.325 109.897 6.385
202103 6.257 111.754 7.378
202106 4.745 114.631 5.455
202109 5.797 115.734 6.601
202112 5.962 117.630 6.679
202203 5.556 121.301 6.036
202206 5.571 125.017 5.872
202209 9.192 125.227 9.673
202212 8.178 125.222 8.606
202303 8.530 127.348 8.827
202306 8.510 128.729 8.711
202309 9.746 129.860 9.890
202312 10.662 129.419 10.856
202403 11.206 131.776 11.206

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Innoviva  (NAS:INVA) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Innoviva Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Innoviva's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Innoviva (Innoviva) Business Description

Industry
Traded in Other Exchanges
Address
1350 Old Bayshore Highway, Suite 400, Burlingame, CA, USA, 94010
Innoviva Inc develops biopharmaceutical drugs in the antibiotic, respiratory, and digestive realms. Theravance's respiratory compounds are in late-stage trials for asthma and chronic obstructive pulmonary disease. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others. The firm collaborates with and receives funding from GlaxoSmithKline.
Executives
Marianne Zhen officer: Chief Accounting Officer C/O INNOVIVA, INC., 2000 SIERRA POINT PARKWAY, SUITE 500, BRISBANE CA 94005
Stephen Basso officer: Chief Financial Officer C/O INOZYME PHARMA, INC., 321 SUMMER STREET, SUITE 400, BOSTON MA 02210
Margaret Koziel officer: Chief Medical Officer C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Alexander J Denner 10 percent owner C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Deborah Birx director 3300 LOWELL STREET NW, WASHINGTON DC 20008
Sarissa Capital Management Lp 10 percent owner 660 STEAMBOAT ROAD, GREENWICH CT 06830
Pavel Raifeld officer: Chief Executive Officer 1350 OLD BAYSHORE HIGHWAY, SUITE 400, BURLINGAME CA 94010
Sapna Srivastava director C/O MYOS CORPORATION, 45 HORSEHILL ROAD, SUITE 106, CEDAR KNOLLS NJ 07927
Larry G. Edwards officer: CEO of La Jolla Pharmaceutical C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472
Plc Glaxosmithkline 10 percent owner 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Mark Dipaolo director 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Kostas D Odysseas director 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Sarah J. Schlesinger director C/O ARIAD PHARMACEUTICALS, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Jules Haimovitz director 601 108TH AVENUE NE, SUITE 1200, BELLEVUE WA 98004
George Bickerstaff director C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511